Compare Crocs, Inc. (CROX) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crocs, Inc. vs IDEXX Laboratories, Inc. — how do they compare? Crocs, Inc. trades at $116.68 (market cap $5.60B), while IDEXX Laboratories, Inc. trades at $512.76 (market cap $40.43B). The key difference: IDEXX Laboratories, Inc. is far larger — about 7.2× Crocs, Inc.'s market cap, and Crocs, Inc. is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crocs, Inc. for 96 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| CROX | IDXX | |
|---|---|---|
Market Cap | $5.60B | $40.43B |
Volume | 1,026,773 | 692,164 |
Sector | Consumer Cyclical | Health |
52-Week High | $141.19 | $766.68 |
52-Week Low | $73.39 | $504.70 |
Typical Hold Time | 96 Days | 46 Days |
Enterprise Value | $7.12B | $41.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CROX trades at $115.20, down 4.18% amid bearish technical signals, though valuation metrics appear attractive with a P/E of 10.23 and P/S of 1.46. Recent earnings beats and a 51% analyst buy rating support fundamental strength, but 2025 net income turned negative due to tax impacts. The stock faces resistance near $116-119 with support at $114.
Outlook remains mixed: strong brand positioning and earnings momentum contrast with technical weakness and recent profitability challenges. The consensus price target of $136.78 suggests 19% upside, but investors should weigh competitive pressures and consumer spending volatility against valuation appeal.
IDEXX Laboratories (IDXX) trades at $506.67, down 1.7% on the day, with technical indicators showing bearish momentum despite strong fundamental performance. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS of $4.27 exceeding expectations of $3.94. Recent developments include the acquisition of CoVetAI to enhance veterinary workflow intelligence and expansion of diagnostic testing platforms internationally. Revenue growth remains robust at $4.3 billion for 2025, with net income margins exceeding 25%.
The stock presents a compelling growth story with strong profitability metrics and analyst consensus pointing to significant upside potential (average price target $665). However, current technical weakness and premium valuations (P/E 36.06) create near-term headwinds. Key risks include foreign exchange pressures and potential slowdown in U.S. veterinary visits, while institutional ownership trends show mixed positioning among major funds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crocs, Inc.
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable geographic segments of the company include Americas, Asia pacific, and EMEA.
Read more on CROX →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
